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Non-coding rRNA-mediated preferential killing in
cancer cells is enhanced by suppression of autophagy
in non-transformed counterpart
CJ Hwang
1, JR Fields
1 and Y-H Shiao*
,1
Interest to anticancer agents targeting rRNA biogenesis is growing. Cis-non-coding rRNAs, alternative to primary rRNA, have
been shown to regulate rRNA biogenesis. We have recently detected bidirectional non-coding rRNAs that carry ribozyme-like
properties. Anti-antisense oligonucleotidescomplementarytoantisensenon-codingrRNAsmarkedlystabilizedthe bidirectional
transcripts and induced cell death in mouse lung cells. Here, we demonstrated that the same oligonucleotide killed mouse lung-
cancer cells preferentially, compared with non-cancer sister lines, suggesting its potential utility for cancer treatment. A human
version of anti-antisense oligonucleotide, complementary to an rDNA intergenic site, mediated apoptosis primarily in cancer
cells. Autophagic activation was largely undifferentiable between the anti-antisense and other oligonucleotides and accounted
forthe undesired cytotoxicityinnon-cancercells.Co-treatmentwithchloroquine,anautophagy inhibitor,reduced cytotoxicityin
the non-cancer cells, but retained the anti-antisense-mediated killings in cancer cells. Furthermore, the anti-antisense
oligonucleotidestabilizedbidirectionalnon-codingrRNAs predominantly inhumancancer cellsandperturbedrRNA biogenesis.
Contributions of non-coding rRNAs to cell death were proven by transfection of in –vitro-synthesized transcripts. Taken
together, cancer/non-cancer cells respond differently to stabilization of non-coding rRNAs, and such differential responses
provide a window of opportunity to enhance anticancer efﬁcacy.
Cell Death and Disease (2011) 2, e239; doi:10.1038/cddis.2011.110; published online 8 December 2011
Subject Category: Cancer
Transcription of the rDNA, a tandemly repeated gene and
highly conserved across unicellular and multicellular organ-
isms,
1 is coordinated by many proteins, including oncogenes
and tumor suppressors.
2,3 Phosphorylation of several trans-
cription factors, such as UBF, TIF-IA, and TIF-IB/SL1, by
kinases in EGFR signaling and mTOR-related pathways is
essential for the activation of rDNA transcription. Proliferating
cells elevate the demand of rRNA production and subsequent
ribosomal assembly to support growth and survival. Increase
of nucleolar organizer region in size or number, representing
actively transcribed rRNA loci, has been a classical biomarker
for tumor phenotype.
4,5 The initial 47S transcript undergoes
serial steps of rRNA processing to generate mature 18S,
5.8S, and 28S rRNAs, starting with excision of the Leader
sequence from the 50 external transcribed spacer (ETS) at
about þ650 nucleotide in mice and at the þ414 site in
humans.
6,7 Many therapeutic drugs targeting rRNA bio-
genesis,eitherattranscriptionorprocessingstep,arecommon
regimens for anticancer treatment.
8 It has been shown that
cisplatin suppresses rRNA transcription by displacing UBF
and RNA polymerase I to the periphery of the nucleolus
9 and
5–ﬂuorouracil disrupts rRNA processing.
10,11
The rRNA transcription is also regulated by nucleolar-
remodeling complex, which promotes gene silencing upon
binding of an intergenic promoter rRNA of about 100–200
nucleotides in mouse ﬁbroblast cells.
12,13 Non-protein-coding
RNAs, other than rRNA, are ubiquitously expressed in
60–70% of mammalian genomes and frequently regulate
the transcription of nearby primary transcripts.
14–16 Of these
transcription-rich clusters, over 20% in humans and about
72% in mice are expressed as sense–antisense pairs.
17–19
The levels of sense and antisense non-coding RNA may be
concordant, that is, concurrently upregulated or downregu-
lated, or discordant.
16,19 In the rDNA gene, we detected
bidirectional cis-non-coding rRNAs (nc-rRNAs) in mouse lung
epithelial cellsand they followed a feed-forward or concordant
mechanism to elevate sense/antisense nc-rRNAs upon
introduction of antisense oligonucleotides and to perturb
rRNA biogenesis (Supplementary Figure S1a). Oligonucleo-
tides complementary to antisense nc-rRNAs were more
potent than those pairing with sense nc-rRNAs to trigger
cell death in mouse lung cancer cells (Supplementary
Figure S1b). As stabilization of nc-rRNAs is concurrent with
perturbation of rRNA biogenesis, this opens an opportunity to
explore the potential of targeting nc-rRNAs for anticancer
treatment. In this study, we applied antisense strategy to
induce preferential cell death in mouse and human lung
cancer cells. We determined the efﬁcacy of cancer-selected
Received 19.7.11; revised 06.9.11; accepted 19.9.11; Edited by A Stephanou
1Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, Frederick, MD, USA
*Corresponding author: Y-H Shiao, Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, Building 538, Room 205, NIH, West 7th Street,
Frederick, MD 21702, USA. Tel: þ301 846 1246; Fax: þ301 846 5946; E-mail: shiaoy@mail.nih.gov
Keywords: non-coding RNA; rRNA; sense antisense; apoptosis; autophagy; anticancer
Abbreviations: nc-rRNA, noncoding rRNA; LNA, locked nucleic acid; RT-PCR, reverse transcription-polymerase chain reaction; ETS, external transcribed spacer;
LDH, lactate dehydrogenase; NoRC, nucleolar remodeling complex; PBS-T, phosphate-buffered saline-Tween 20
Citation: Cell Death and Disease (2011) 2, e239; doi:10.1038/cddis.2011.110
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddiscell elimination among antisense oligonucleotides comple-
mentary to various regions of sense and antisense nc-rRNAs.
Mechanisms of oligonucleotide-mediated cytotoxicity, includ-
ing apoptosis and autophagy, were examined in human lung
cells. Their relevance to preferential killings in cancer cells
and reduction of cytotoxicity in non-cancer counterpart are
discussed.
Results
Potent cancer cell inhibition by oligonucleotides pairing
with antisense nc-rRNAs. Two antisense oligonucleotides,
LNA1-S and LNA1-AS (Figure 1a), complementary to mouse
antisense and sense nc-rRNAs, respectively, were ﬁrst
applied to test whether stabilization of nc-rRNAs provides
any advantage to inhibit lung cancer cells predominantly. The
cell viability was compared among treatments and was
signiﬁcantly reduced by LNA1-S, relative to either iFect
vehicle control or LNA1-AS, in E10/E9 and C10/A5 pairs of
non-cancer/cancer sister lines (Figure 1b). The degree of
reduction, calculated by percentage of decrease in formazan
intensity, showed that the E9 and A5 cancer lines are
more sensitive to LNA1-S-mediated cell inhibition than
their non-cancer counterparts, E10 and C10. This presents
the evidence that stabilization of nc-rRNAs by targeting
antisense nc-rRNAs is a promising strategy for anticancer
treatment.
To extend the anticancer potential of nc-rRNA stabilization
to humans, the subsequent study focused on human lung
cells. Among several oligonucleotides (Figure 1a), the 86S
complementary to the antisense nc-rRNA at  86 to  69
upstream from the transcription start site was mostly effective
in reducing cell number in H441 and A549 cancer cells
(Figure 2a and Supplementary Figure S2). Higher degree of
reduction in cell density was appreciable in the 86S treatment,
compared with 84AS (Figure 2a). The 86S was therefore
chosenforfurthercharacterizationofmechanismsthatleadto
its superior cell inhibition in reference to the 84AS or a non-
speciﬁc scramble oligonucleotide control. The cytotoxic
induction by 86S relative to 84AS increased as a function of
the dosing concentration (Figure 2b). The same trend was
observed using the non-speciﬁc oligonucleotide. An approxi-
mately 2–fold stronger killing efﬁciency by the 86S treatment
over the 84AS was seen in H441 and A549 cancer lines at
30 and 40nM. In contrast, similar killing efﬁciency between
86S and 84AS treatment, also visualized in Figure 2a, was
observed in non-cancer HPL regardless of dosing concentra-
tion, likely a result of background stress response to
oligonucleotides. Undesired cytotoxicity in non-transformed
HPL following 86S or 84AS treatment prompted us to
determine mechanisms of cell death that may lead to a
better treatment strategy for killing human cancer cells
predominantly.
Activations of apoptosis and autophagy and their
relevance to anticancer efﬁcacy. Small but signiﬁcant
increase of apoptosis was detected 24h after
oligonucleotide treatment, primarily in 86S-treated H441 and
Figure1 Oligonucleotidescomplementarytonc-rRNAsandpreferentialanticancereffects.(a)Oligonucleotide-targetingsitesonsenseandantisensenc-rRNAs.Hatched
bars:Lockednucleicacid(LNA)gapmersformouse lungcells;unﬁlledbars:regularoligonucleotides forhumanlungcells.(b)Cellviabilityofmouse lungcancerlines(A5and
E9)andcorrespondingnon-cancersisterlines(C10andE10),respectively,24haftertransfectionof50nMLNAs.*Po0.05,**Po0.01,comparedwithiFectvehiclecontrolor
LNA1-AS from triplicate samples. Error bars denote ±standard error. NTS, nontranscribed spacer; ETS, external transcribed spacer; ITS, internal transcribed spacer
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Cell Death and DiseaseA549 cancer lines, compared with non-speciﬁc scramble or
84AS oligonucleotide control (Figure 3). On the contrary, no
elevation of apoptosis was detected in HPL non-cancer cells by
the 86S treatment at this time point. The second dosing of
40nM oligonucleotides did not enhance the degree of apoptosis
established at 24h in cancer cells, but the fraction containing
fragmented non-apoptotic cells was enlarged in the 86S-treated
H441 cells (Figure 4). Other cell death mechanisms might be
involved. The signiﬁcant increase of apoptotic fraction in
non-speciﬁc oligonucleotide- or 84AS-treated cells, compared
with iFect vehicle control, in single (24h) and double (48h)
treatments suggests a minor degree of cytotoxicity resulting
from the presence of oligonucleotide per se. There were not
any consensus changes across three phases of cell cycle at
24 and 48h following the 86S treatment (Supplementary
Figures S3 and S4).
Apoptosis was further validated by upregulation of cleaved
PARP and/or activated caspase 7, predominantly in
86S-treated cells (Figure 5a). H441 and A549 showed a
steady apoptotic induction with increased levels of cleaved
PARPandcaspase7at48h.Thetimingmatchedtotheapop-
totic phenotype representing internucleosomal DNA breaks
(Figures 3 and 4). In contrast, HPL non-cancer cells followed
a very weak apoptotic response to the 86S, evidenced by null
Figure 2 Selectivity of anticancer effects by oligonucleotides in human lung cells. (a) Microscopic images (scale bar, 100mm) of non-transformed HPL and two cancer
lines (H441 and A549) at 48h after two transfections of 50nM of 86S, 84AS, or iFect vehicle at 0 and 24h. Bright granules represent detached dead cells. (b) Quantitative
assay for the percentage of detached cells relative to the total cell population 48h after single transfection of 86S (circle) or 84AS (triangle) at selected concentrations
(*Po0.05; **Po0.01; duplicate samples with triplicate measurements). Error bars denote ±standard deviation. Background levels of cytotoxicity in iFect-treated controls
were 7.1, 7.1, and 2.9% for HPL, H441, and A549, respectively. The killing efﬁciencies, calculated by fold changes of cytotoxicity in reference to corresponding iFect controls,
were listed in the bottom right panel for 86S and 84AS treatments (Tx)
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Cell Death and Diseaseto minimal changes of the internucleosomal DNA breaks
(Figures 3 and 4) and cleaved caspase 7 level (Figure 5a)
at 24 and 48h. This suggests that apoptosis is not a major
contributor for the undesired cytotoxicity in HPL, shown
in Figure 2b. Also, changes of PARP levels in HPL did
not correlate with internucleosomal DNA breaks, raising
the possibility that PARP is not involved in apoptosis in
non-transformed cells. The differential response to apop-
tosis between cancer and non-cancer cells further
supports that cancer-selected cell destruction may be
obtained through apoptotic activation by targeting antisense
nc-rRNAs.
In addition to apoptosis, conversion of LC3B-I to LC3B-II
protein, indicative of autophagy, was observed in 86S-
treated cells (Figure 5a). The 84AS and/or non-speciﬁc
oligonucleotides were also tested in some experiments and
their apoptotic inductions were clearly less effective than the
86S treatment; however, the autophagic responses were
mostly undistinguishable among oligonucleotides. On the
contrary, the timing of autophagic activation relative to vehicle
control varied among cells, and therefore the 86S-mediated
autophagy was subsequently classiﬁed into steady (occur-
rence at both 24 and 48h) and weak response (occurrence
at 48h only). HPL and A549 showed steady response,
whereas H441 followed a late or weak autophagic activation.
The autophagy was conﬁrmed by the presence of autophago-
somes (Figure 5b).
Since autophagy has been implicated in both cell killing and
survival,
20,21 we next determined if co-treatment of oligo-
nucleotide with chloroquine, an autophagy inhibitor, would
enhance or suppress overall cytotoxicity. As shown in
Figure 6, suppression of oligonucleotide-induced cytotoxicity
by chloroquine co-treatment was demonstrated in HPL and
A549 cells. The degrees of inhibition, calculated by relative
reduction of killing efﬁciency after chloroquine co-treatment,
ranged from about 40% in HPL to over 50% in A549,
supporting that 86S and even non-speciﬁc oligonucleotide
induce cytotoxicity largely by autophagy in these two cells.
ThisisconsistentwiththesteadyautophagicresponseofHPL
and A549 cells, measured by the conversion of LC3B-I to
LC3B-II protein as described above (Figure 5a). In contrast,
killing efﬁciencies of oligonucleotides in H441were not
reduced by the co-treatment with chloroquine, concordant
with its weak response to autophagic activation represented
by little changes in LC3B-II/LC3B-I ratio in Figure 5a. This
impliesthathighdosingconcentrationsofoligonucleotidemay
Figure 3 Induction of apoptosis 24h after single transfection of 50nM oligonucleotides. Comparisons of apoptotic fractions, upper left (UL) and upper right (UR), among
duplicate samples from each oligonucleotide treatment.
#Po0.05, comparison of 84AS or NS with iFect control;
zPo0.05, compared with 84AS; *Po0.05, **Po0.01,
compared with NS. Lower left (LL), fragmented/non-apoptotic fraction; lower right (LR), unaffected cells; NS, non-speciﬁc scramble oligonucleotide; x-axis, propidium iodide
signal for DNA content; y-axis, ﬂuorescein intensity in log scale for apoptosis
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Cell Death and DiseaseFigure 4 Induction of apoptosis after two transfections of 50nM oligonucleotides at 0 and 24h. Comparisons of apoptotic fractions, upper left (UL) and upper right
(UR), among duplicate samples from each oligonucleotide treatment.
#Po0.05, comparison of 84AS or NS with iFect vehicle control;
zPo0.05,
zzPo0.01, compared with
84AS; *Po0.05, **Po0.01, compared with NS. NS, nonspeciﬁc scramble oligonucleotide; x-axis, propidium iodide signal for DNA content; y-axis, ﬂuorescein intensity in
log scale for apoptosis
Figure 5 Activation of apoptotic and autophagic pathways by the 86S. (a) Western blot analyses of apoptotic (cleaved PARP and cleaved caspase 7) as well as
autophagic (conversion of LC3B-I to LC3B-II) markers in cells 24 or 48h (2 transfections at 0 and 24h) after initial transfection of 50nM oligonucleotides. Apoptotic
induction was represented by higher levels of cleaved PARP and/or cleaved caspase 7 relative to the iFect vehicle and/or untreated (UT) controls. (b) The ultra-
structural signature of autophagosomes (arrows) was revealed under transmission scanning microscope. Autophagosomes were also detected in controls that
did not receive oligonucleotides. Images were taken after two transfections of 50nM oligonucleotides at 0h and 24h (scale bar: 2mm). NS, nonspeciﬁc scramble
oligonucleotide
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Cell Death and Diseasebe used along with chloroquine to maximize the anticancer
efﬁcacy and to minimize the cytotoxicity in normal cells.
Stabilization of nc-rRNAs by the 86S oligonucleotide.
The roles of nc-rRNAs in the above differential anticancer
effects were explored next. A human sense nc-rRNA was
reported early
22 and the presence of an antisense nc-rRNA
was conﬁrmed by reverse transcription-polymerase chain
reaction (RT-PCR) and sequencing here (nucleotides þ569
to þ887). Search in GenBank Expressed Sequence Tag
database also identiﬁed many cDNAs showing 495%
homology to the rDNA in antisense orientation. The basal
levels of nc-rRNAs and serial rRNA transcripts, that contain
the Leader sequence, 50ETS, 18S, and 28S regions during
rRNA biogenesis
7,23 were measured ﬁrst to identify
transcripts that may differentiate cancer from non-cancer
cells. In comparison with non-transformed HPL, the levels of
antisense nc-rRNAs and serial transcripts in rRNA bio-
genesis were in general higher in H441 and A549 cancer
cells (Figure 7a), providing evidence that cancer cells acquire
elevated levels of these two groups of rRNA species during
tumorigenesis. The only exception is that the sense
nc-rRNAs were higher in H441 but lower in A549, relative
to HPL. Such variability of sense nc-rRNAs among cancer
lines was reported before.
22 Similar expression proﬁles
between sparse and dense growth support that rRNA
biogenesis remains steady in cancer and non-cancer cells
even at high degree of cell–cell contact.
The transcriptional proﬁles after treatments with 86S and
84AS oligonucleotides were illustrated in Figure 7b. Stabiliza-
tions of both sense and antisense nc-rRNAs were detected,
primarily in detached cells. The loss of viability for detached
cells was validated by the retention of blue dye in trypan blue
exclusion assay. The levels of upregulation for both nc-rRNAs
were signiﬁcantly higher in detached cancer cells induced by
the 86S treatment, compared with 84AS. This provides the
evidence that human bidirectional nc-rRNAs also follow a
feed-forward mechanism, as seen in mouse lung cells, and
are preferentially stabilized by the 86S targeting antisense
nc-rRNAs. No difference between 86S and 84AS treatment in
HPL suggests that increases of nc-rRNAs in non-transformed
cells are induced simply by the presence of oligonucleotide
per se, which may account for the undesired cytotoxicity
(Figures 2b and 6). Strikingly, the levels of sense nc-rRNAs
wereupregulated100-to1000-foldinoligonucleotide-induced
detached cancer cells, whereas only about 10-fold accumula-
tionofthetranscriptwereobservedindetachedHPLcells.Itis
likely that slight accumulation of nc-rRNAs is detrimental to
non-transformed cells, whereas cancer cells tolerate high
levels of the transcripts. Elevations of sense and/or antisense
nc-rRNAs were sporadically detected in adherent cells and
the extent was much lower than detached cells, possibly a
resultofincreasedtranscriptsfromdyingcells,whichwerenot
yet detached.
Concurrent stabilization of nc-rRNAs (Figure 7b) and
induction of cell death (Figure 2b) by the 86S and 84AS
treatments raised a possibility that sense and antisense
nc-rRNAs may function as death mediators. Two lines of
evidence support this hypothesis. First, perturbation of the
rRNA processing, represented by changes of serial rRNA
transcriptscontainingLeadersequence,50ETS,18S,and28S
regions, was accompanied by upregulation of nc-rRNAs in
86S-and 84AS-induced detached cells (Figure 7b). Interfer-
ence of rRNA biogenesis is known to trigger cell destruction
and is a common strategy in selecting anticancer agents.
24–26
Second,strikingaccumulationsofnc-rRNAswereobservedin
detached cells induced by nutrient starvation, namely, no
culture media change for over 1 week (Figure 7b). The rRNA
biogenesis was also profoundly altered by the starvation
treatment.
Induction of cell death directly by in –vitro-synthesized
nc-rRNAs. To test the hypothesis that nc-rRNAs can
mediate cell death directly, in–vitro-synthesized nc-rRNAs
in sense and antisense orientations (Supplementary Table S1)
were transfected into human lung cells. Initial trials of
eight nc-rRNAs using transfection reagent as a control
Figure 6 Differential suppression of oligonucleotide-induced cytotoxicity by
chloroquine (CQ). Cell killing efﬁciency (KE) was calculated as ratio of averaged
cytotoxicityinoligonucleotide-treatedcellsto theiFect vehiclecontrolfromduplicate
samplesintriplicateassays,measured48h afterco-treatmentof25mM chloroquine
with single transfection of 40nM oligonucleotides.
#Po0.05, comparison of NS with
iFect vehicle control; **Po0.01, compared with NS. Error bars denote ±standard
error. UT, untreated; NS, nonspeciﬁc scramble oligonucleotide
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Cell Death and Diseasedetected elevation of cytotoxicity only for 7S ( 244 to þ203)
in the sense direction and two antisense transcripts, 2AS
( 1t o 244) and 8AS (þ203 to  244). The remaining
in –vitro-transcribed nc-rRNAs in sense ( 244 to  1,  409
to  248, and  709 to  486) and antisense ( 248 to  409
and  486 to  709) orientations yielded cytotoxicity similar to
the reagent control. The 7S, 2AS, and 8AS transcripts along
with a control, 1S (nucleotide  244 to  1), were chosen for
further examination under two different dosing condi-
tions (Figure 8). Signiﬁcant increases of cytotoxicity were
readily detectable following transfection of several nc-rRNA
transcripts at 1pmol in HPL and A549. The high degree of
cytotoxicity in HPL at 1pmol recapitulates the susceptibility of
HPL to cell detachment in the presence of 10-fold, not 100s
to 1000s, accumulation of nc-rRNAs (Figure 7b). Majority of
cytotoxic response in H441 began to appear after trans-
fection with 5pmol of the nc-rRNA transcripts. The require-
ment of higher dosing concentration to achieve signiﬁcant
cytotoxicity is consistent with the early observation that H441
maintains and tolerates abundant nc-rRNAs during basal
Figure 7 Levels of nc-rRNAs and rRNA processing transcripts before and after oligonucleotide treatments. (a) The basal levels of nc-rRNAs and serial rRNA transcripts
representingasignatureof rRNAprocessingwerequantiﬁedbyRT-PCRat twogrowthconditionsinuntreatedcells(*Po0.05;**Po0.01;comparedwith HPLfromduplicate
samples). Error bars denote±standard error. (b) Heat map of fold changes of nc-rRNAs and serial transcripts during rRNA biogenesis relative to adherent cells from iFect
vehicle treatment after two transfections of 50nM oligonucleotides at 0 and 24h. The choice of the iFect to obtain fold changes of transcripts avoided the differential effects of
the vehicle itself on nc-rRNAs among cells, where upregulation (sense in A549 and antisense in HPL) and downregulation (antisense in A549) were observed (Data not
shown). The iFect alone did not alter both nc-rRNAs in H441. Color denotes over 2-fold change and/or Po0.05 (red: upregulation; green: downregulation); *Po0.05,
compared with 84AS in corresponding adherent and detached cells
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Cell Death and Diseasegrowth (Figure 7a). Killing efﬁciencies of both HPL and A549
were enhanced at the 5pmol dosing concentration as
predicted, but the fold increases relative to corresponding
treatments at 1pmol were greatly enhanced in A549 only.
The fold changes were 1.3, 1.5, and 1.9 in HPL and 2.5, 3.0,
and 5.6 in A549 for 7S, 8AS, and 2AS treatments,
respectively. The degrees of changes in killing efﬁciency
from 1pmol to 5pmol of nc-rRNAs were relatively small in
HPL, implying that further increases of nc-rRNAs would still
induce cytotoxicity predominantly in cancer cells. This
preferential killing in A549 cancer cells over HPL non-
cancer line using in –vitro-synthesized nc-rRNA transcripts
reminisces the anticancer effects that are induced by
stabilization of nc-rRNAs using the 86S oligonucleotide.
Discussion
Inthis study,we demonstratedthat cis-bidirectional nc-rRNAs
are potential targets for cancer-speciﬁc therapy. The 86S
oligonucleotide is more effective than the 84AS in the
induction of apoptotic cell death in human lung cancer cells.
This recapitulates the killing efﬁcacy of targeting antisense
nc-rRNAinmouselungcancercells.Althoughbotholigonucleo-
tides stabilized sense and antisense nc-rRNAs, the degree of
upregulation was much higher and more steps of rRNA
biogenesis were affected in cells committing to multiple death
pathways following the 86S treatment, compared with 84AS.
This provides evidence that antisense nc-rRNA is a promising
target for drug discovery. Its stabilization may trigger massive
increaseofcomplementary sensenc-rRNA,similar totypesof
concordant transcripts described before.
16,19 Also, cancer
cells, relative to non-cancer counterpart, are prone to the
stabilization of nc-rRNAs, which are proven to be cell death
mediators by transfection of synthetic transcripts, supporting
the idea that formulation of drugs to stabilize antisense
nc-rRNAs may preferentially eliminate cancer cells. Such
regimen is further beneﬁted by co-treatment with chloroquine
to reduce 86S-mediated autophagy in HPL non-cancer cells.
Although antisense nc-rRNAs are upregulated to a lesser
extent than sense transcripts in response to the 86S
treatment, detection of cytotoxicity following direct introduc-
tion of synthetic antisense nc-rRNA suggests that the 86S
exerts dual killing effects by sense and antisense nc-rRNAs.
Previously, an intergenic nc-rRNA at around –142 to –43
nucleotide region, also known as promoter rRNA, was
detected in mouse and human cells
12,13 and was shown to
form a stem-loop structure essential for the binding of TIP5, a
component of nucleolar remodeling complex (NoRC). Disrup-
tion of the stem-loop structure or ectopic expression of the
nc-rRNA transcript promoted migration of the NoRC from
nucleolustonucleoplasmandupregulatedthelevelofthe47S
pre-rRNA that contains the Leader sequence. The 86S in the
current study is mapped to the stem-loop core region. The
increase of the 47S pre-rRNA following the 86S treatment
might be initially interpreted as displacement of NoRC from
the nucleolus by excessive sense nc-rRNA and subsequent
relief of NoRC-mediated gene silencing, indicative of high
demand for rRNA biogenesis.
12 However, such a burst of
rRNA transcript level is concomitant with cell death, suggest-
ing that the increase of the 47S rRNA is a ramiﬁcation of
perturbation in the rRNA processing. This assumption is
supported by a report ﬁnding disruption of rRNA processing in
human cancer cells after expression of exogenous sense and
antisensenc-rRNAsfromthe50ETSregion.
27Thealterationin
the rRNA processing is further revealed by the changes of
other pre-rRNA intermediates that contain 50ETS, 18S, and
28S regions. It is likely that level changes of serial pre-rRNA
transcripts during processing in detached cancer cells is
a result of duplex formation with upregulated antisense
nc-rRNAs or competition with excess sense nc-rRNAs. The
efﬁcacy of cancer-selected killing by the 86S, better than
84AS, advocates that continuous screening for extensive
regions of antisense nc-rRNAs with oligonucleotides may
identify additional potent anticancer targets. Besides the
strategy to upregulate nc-rRNAs by oligonucleotides, in
Figure 8 Direct induction of cytotoxicity by in vitro-synthesized nc-rRNAs. Cell
killing efﬁciency (KE) was calculated from averaged cytotoxicity in cells 48h after
single transfection of selected nc-rRNA transcripts at 1 and 5pmol in 3ml cell
culture in reference to the TransIT transfection (TF) vehicle control from duplicate
samples in triplicate assays.
#Po0.05, comparison of 1S with TF; **Po0.01,
comparedwiththe1Streatment. Errorbars denote±standarderror. UT, untreated
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Cell Death and Diseasetheory, it is feasible to utilize the ribozymatic property of
nc-rRNAs, demonstrated previously in mouse cells (Personal
communication), for discovery of small-molecule ribozyme
inhibitors.
Several agents known to interfere with rRNA transcription
and processing
8 are ﬁrst-line anticancer therapy, such as
cisplatin for advanced non-small-cell lung carcinomas and
5-ﬂuorouracil for colon cancers.
28,29 The list of agents
inhibiting various stages of rRNA biogenesis continues to
grow.
26,30,31 Furthermore, EGFR signaling and mTOR-
related pathways have been linked to rRNA biogenesis.
2,3,8
It is reasonable to believe that tyrosine kinase inhibitors,
32 for
example, geﬁtinib and erlotinib, and mTOR antagonists,
33
such as temsirolimus, may also suppress rRNA biogenesis
indirectly. The anti-nc-rRNA approach to selectively eliminate
cancer cells, described in the current study, provides proof
of principle to develop antisense oligonucleotides for anti-
cancer treatment targeting rRNA biogenesis. This strategy
may be also applied to other antisense and sense non-coding
transcripts, reported to be differentially expressed at genome
scale in cancers.
34
Materials and Methods
Cell lines and culture. Non-transformed peripheral lung cells of BALB/c
mouse origin, C10 and E10, and corresponding spontaneously transformed A5 and
E9 sister lines, respectively, were obtained and cultured, as previously described.
35
HPL1D,anon-transformedlinederivedfromhumanperipherallungepithelium,was
obtained from Drs. T Takahashi and A Masuda and maintained in a standard
medium, as described before,
36 with some modiﬁcations to replace fungizone and
fetal calf serum with 4mM glutamine and 1% fetal bovine serum (Gemini
BioProducts, West Sacramento, CA, USA). Human lung adenocarcinoma cell lines,
A549 and H441, were purchased from American Type Culture Collection
(Manassas, VA, USA) and were propagated routinely in RPMI 1640 media
(Invitrogen, Carlsbad, CA, USA). To minimize the variation due to culture
formulation, H441 and A549 were temporarily grown in the same media as the HPL
throughout 24 or 48h transfection with oligonucleotides.
RNA extraction, RT and PCR. Total RNA was extractedusing RNeasy Mini
RNA kit (Qiagen, Germantown, MD, USA), according to the manufacturer’s
protocol. Residual DNA was removed by recombinant DNase I and total RNA was
puriﬁedandquantiﬁed,aspreviouslydescribed.
22RTtogeneratecDNAwascarried
out at 501C using the SuperScript III kit (Invitrogen), according to the
manufacturer’s instruction, and gene-speciﬁc primers (Supplementary Table S1).
SixregionsofhumanrRNAgene,correspondingtoserialtranscriptsthatcontainthe
Leader sequence, 50ETS, 18S, and 28S regions in rRNA processing and putative
nc-rRNAs in sense as well as antisense directions, were quantiﬁed in reference to
beta-Actininternalcontrol.Quantitativereal-time PCRfor all regionswas performed
in the Chromo4 System (Bio-Rad, Hercules, CA, USA). Each reaction of a total
volume of 20ml contained 0.5mM gene-speciﬁc primer pairs (Supplementary Table
S1),1  SYBRGreenPCRMix(Qiagen),and2mlofcDNA.PCRwascarriedoutat
951C for 15min, followed by 35–40 cycles of 941C for 15s, 651C for 20s, and
721C for 30s. Mouse transcripts were detected using the following primers and
551C annealing temperature at PCR step. RT primers were gagacaaacctggaacg
(for Leaderand 50ETS rRNAs), acctatctccaggtccaatagg (for sense nc-rRNAs), poly-
T20 (for antisense nc-rRNAs), and gctgtagccgtattcatt (for the Gapdh internal
control). The corresponding PCR primers for each region were gtggagagtcccga
gtactt/ggggcaagacagttactgata (Leader sequence), acgtgtttcactttggtcgt/acctcgacgct
tacaagaaa (50ETS), gcggttttctttcattgacc/acctatctccaggtccaatagg (sense nc-rRNAs),
gcggttttctttcattgacc/ccttaaatcgaaagggtctctt (antisense nc-rRNAs), and cctggagaaa
cctgccaagtat/gagtgggagttgctgttgaagtc (Gapdh). Ct (cycle at threshold) values were
determined by the Opticon Monitor 3 software (Bio-Rad). Intensity was subse-
quently converted using the 2
 Ct formula. Two RTs and a total of four PCRs were
carried out for each of duplicate samples.
Transfection. HPL and H441 cells were seeded in six-well plates at 2 10
5
cells/well and A549 at 1 10
5 cells/well. Cells were transfected with
oligonucleotides (Figure 1a and Supplementary Table S1) using RNAiFect kit
(Qiagen)accordingtothemanufacturer’sinstructionandfollowingtheformulationof
1:6 oligonucleotide (mg) to RNAiFect reagent (ml) ratio. The transfection efﬁciency
was determined using the Label IT RNAi Delivery Control (Mirus, Madison, WI,
USA) and was comparable among cell lines. For the co-treatment with chloroquine,
50mlof1.575mMchloroquinein1  phosphate-bufferedsalinesolutionwasadded
immediately aftertransfection, to constitutea 25mM ﬁnal chloroquineconcentration.
In vitro-transcribed nc-rRNAs (1–5pmol) were transfected in a six-well plate format
using TransIT-mRNA Transfection kit (Mirus), according to the manufacturer’s
protocol.
Cell viability, cytotoxicity, apoptotic DNA break, and cell cycle
analyses. Cell viability was quantiﬁed by CellTiter 96 AQ one solution cell
proliferation kit (Promega, Madison, WI, USA) converting a tetrazolium compound
to formazan for cells cultured in a 96-well plate. The CytoTox 96 Non-Radioactive
Cytotoxicity Assay kit (Promega) was used to measure lactate dehydrogenase
(LDH) release, indicative of cytotoxicity. In brief, cells were transfected with
oligonucleotides in 6-well plates as aforementioned. Three 50ml aliquots
of supernatant before and after direct addition of a 300ml of Triton X-100
(9% v/v in water) lysis solution were transferred to 96-well plates at designated
time points for each of duplicate samples.The intensity of formazan, produced from
LDH reaction, was quantiﬁed at 492nm after 30-min incubation. The level of
cytotoxicity was expressedas relative intensityof formazan in supernatant to that of
total lysate. Apoptosis as a result of internucleosomal DNA breaks and cell cycle
fractions were quantiﬁed using the Apo-BrdU kit (Phoenix Flow Systems,
San Diego, CA, USA) according to manufacturer’s manual. More than 10000
stained cells were sorted and counted by ﬂow cytometry. WinMDI 2.8 (http://
www.cyto.purdue.edu/ﬂowcyt/software.htm) and Cylchred (http://www.facslab.
toxikologie.uni-mainz.de/engl.%20Websites/Downloads-engl.jsp) software were
used to calculate the fractions of apoptotic cells and 3 phases of cell cycle,
respectively.
Transmission electron microscopy. In situ processing technique of
cultured cellsin6-well platefor thetransmissionelectronmicroscopywas described
previously.
37 Thin-sections (90nm) were mounted on 150 mesh grids, stained in
uranylacetateandleadcitrate,stabilizedbycarbonevaporation,andexaminedwith
anelectronmicroscope(Hitachi,Tokyo,Japan)at80kV.Imageswerecapturedwith
a high resolution CCD camera (AMT, Danvers, MA, USA).
Western blot analysis. Cells seeded in 6-well plates were washed twice with
phosphate-buffered saline (pH 7.4) and lysed with 100ml CellLytic MT Mammalian
Tissue/Lysis Extraction reagent (Sigma, St. Louis, MO, USA) with inclusion of
1  CompleteMiniProteaseInhibitorCocktail(RocheAppliedScience,Mannheim,
Germany). Protein concentration was measured using the BCA Protein Assay kit
(Thermo Scientiﬁc, Wilmington, DE, USA). Proteins were resolved in 4–12%
NOVEX NuPAGE Bis-Tris gel (Invitrogen) and electroblotted onto PVDF
membranes (Bio-Rad) at 32V for 1.5h. Membranes were blocked for 2h at room
temperature with 5% non-fat powder milk in 0.01% Tween 20/phosphate-buffered
saline (PBS-T) solution and then probed with speciﬁc primary rabbit antibodies
against cleaved PARP (1:500 dilution), cleaved caspase 7 (1:500), LC3BI and II
(1:500), and beta-Actin (1:20000) overnight at 41C. After multiple washes with
PBS-T, blots were incubated at room temperature for 1.5h with donkey anti-rabbit
IgG secondary antibody conjugated with horseradish peroxidase (1:500 for PARP,
caspase 7, and LC3B; 1:1000 for beta-Actin). After washes, blots were developed
using a chemiluminescence ECL and ECL Plus kit (Amersham, Piscataway, NJ,
USA) for beta-Actin/LC3B and PARP/caspase 7, respectively, and were exposed
to X-ray ﬁlm (Amersham). Beta-Actin served as a loading control.
In vitro transcription. The templates for in vitro transcription were generated
by PCR using primer pairs listed in Supplementary Table S1. Transcription was
carried out at 371C for 18h using 0.5–1.0pmol DNA template and MEGAscript
T7 kit (Applied Biosystems, Carlsbad, CA, USA) and the transcripts were
subsequently puriﬁed with MEGAclear kit (Applied Biosystems) according to the
manufacturer’s instructions. The sizes and integrity of transcripts were veriﬁed in
Tris-Urea polyacrylamide gel (Invitrogen).
Statistical analysis. Student’s t-test was applied to determine the differences
of cytotoxicity, apoptosis, cell cycle fraction, nc-rRNAs, and serial transcripts
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nc-RNAs. The differences between comparisons were considered signiﬁcant
if P-values were o0.05.
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